These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12164480)

  • 21. Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats.
    Miller A; Carr S; Rabbitts T; Ali H
    MAbs; 2020; 12(1):1752529. PubMed ID: 32316838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A revival of bispecific antibodies.
    Kufer P; Lutterbüse R; Baeuerle PA
    Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
    [No Abstract]   [Full Text] [Related]  

  • 24. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    Parren PW; Burton DR; Bradbury A; Huston JS; Carter PJ; Veldman T; Chester KA; Larrick JW; Alfenito MR; Scott JK; Weiner LM; Adams GP; Reichert JM
    MAbs; 2015; 7(6):981-8. PubMed ID: 26421752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.
    Yu X; Marshall MJE; Cragg MS; Crispin M
    BioDrugs; 2017 Jun; 31(3):151-166. PubMed ID: 28466278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
    Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
    J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward the production of bispecific antibody fragments for clinical applications.
    Carter P; Ridgway J; Zhu Z
    J Hematother; 1995 Oct; 4(5):463-70. PubMed ID: 8581386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation.
    Debaene F; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Anal Chem; 2013 Oct; 85(20):9785-92. PubMed ID: 24007193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody engineering for therapeutics.
    Presta L
    Curr Opin Struct Biol; 2003 Aug; 13(4):519-25. PubMed ID: 12948783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Overview of recent monoclonal antibody therapy].
    Ozeki I; Imai K
    Nihon Rinsho; 2002 Mar; 60(3):457-62. PubMed ID: 11904958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific antibody conjugates in therapeutics.
    Cao Y; Lam L
    Adv Drug Deliv Rev; 2003 Feb; 55(2):171-97. PubMed ID: 12564976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
    Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
    Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
    MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
    Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
    Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.
    Beck A; Carter PJ; Gerber HP; Lugovskoy AA; Wurch T; Junutula JR; Kontermann RE; Mabry R
    MAbs; 2013; 5(3):339-57. PubMed ID: 23493119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.